HIV vaccine candidate successfully optimised for industrial production

Natalia Elliot | October 30, 2024 | News story | Research and Development HIV, HIV/AIDS, Naobios, Sumagen, Vaccine, agreement 

Sumagen Canada Inc, a biotech company based in both South Korea and Canada has partnered with CDMO Naobios to industrialise Sumagen’s human immunodeficiency virus (HIV) -1 vaccine candidate (SAV0001) at bench scale.

First of its kind in human vaccine trials, SAV001 is a whole-killed and genetically modified HIV vaccine. During phase 1 of the clinical trial, NCT01546818, the vaccine demonstrated safety for human use. The trial used 33 participants and results show that SAV001 triggered anti-HIV immune responses, which was reported back in 2016.

Dr Sangkyun Lee, president of Sumagen stated: “We are thrilled to have reached such a strategic industrial milestone within expected initial timelines, which is extremely significant due to the initial project delays resulting from the COVID-19 pandemic. This achievement solidifies our trust in Naobios to help our HIV-1 vaccine reach the crucial phase 2 trials, bringing us closer to delivering a vaccine to patients in need.”

Advertisement

The partnership agreement, which was signed in April earlier this year, stated terms of manufacturing which have been achieved by Naobios within the initial schedule. Both companies are focusing on industrial-scale up activities until mid 2025, which will be immediately followed by cyclic guanosine monophosphate (cGMP) production in order to support phase 2 of the trial, according to the press release.

Natalia Elliot

30/10/24

Related Content

drug-trials

BioNet receives positive EMA opinion on new pertussis vaccine

BioNet has received a positive opinion from the Committee for Medicinal Products for Human Use …

Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON

Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based …

European Commission approves HIV prevention injection

The European Commission (EC) has granted marketing authorisation for Gilead Science’s Yeytuo (lenacapavir), the first …

The Gateway to Local Adoption Series

Latest content